T17 // glp1//2026-08-21

Obesity Drugs Go Mass Market

just starting → still early days, the evidence trail is short

today's evidence: no read yet

today in one lineno new read today, yesterday's evidence still stands

Weight loss drugs are moving from a luxury for the well insured to a mass market product. Pills that need no injection and new government backed pricing widen who gets treated, and the volume winners are Lilly's franchise, the strongest challenger, and the firm selling components into every pen

what the chip and the curve mean

the chip is what today's evidence says: green means the world moved the way this bet needs, red means it moved against it. it reads the day, not the money. the curve above places the whole bet: early on the left, crowded and cooling on the right, from the evidence trend and how loudly the crowd is talking about these names (counted nightly across Reddit, Hacker News, StockTwits and Google searches, with the market's own chasing as the stand-in until that count has history). the receipts quietly keep track of all of it.

// the deal, written down first

both lines went down before the money did, and they never get edited.

KILL IF

The expansion stalls. Treated patient counts flatten, insurers keep dropping coverage, or Lilly's obesity growth rate falls to Novo's for two straight quarters

DOUBLE DOWN IF

Government coverage enrollment accelerates, pill prescriptions keep compounding well past launch, or big pharma buys one of the challengers at a rich premium

// the companies · why these, and what their numbers say

LLYEli Lilly, the first trillion dollar drug company. Its shot and pill franchise is taking most of the obesity market's growth

VKTXViking Therapeutics holds the strongest obesity drug not yet owned by a giant. Part science bet, part buyout bet

WSTWest Pharmaceutical makes the stoppers and injector parts inside the pens. It wins on volume no matter which drugmaker wins

company mkt cap rev growth gross margin fwd p/e fcf margin vs 52w high earnings

LLYEli Lilly $1.1T +47.7% 83.4% 27× +13.9% -2.8% Oct 29

VKTXViking Therapeutics $3.9B — 0.0% -8× — -21.9% —

WSTWest Pharmaceutical $24.8B +13.8% 36.8% 35× +8.4% -8.6% —

what these words mean

mkt cap what the whole company costs to buy · rev growth how much faster sales are running than a year ago · gross margin what is left of each sale before running the business · fwd p/e how many years of expected profit you pay for one share, and (t) means last year's profit where nobody forecasts next year's · fcf margin the slice of sales that ends up as spare cash · vs 52w high how far below its best price of the last year the share sits. these numbers refresh daily from Yahoo Finance.

// the last 90 days · these names against the market they trade in

LLY +20.7% VKTX +9.9% WST +11.7% XLV +18.5%

// the prices · last close 2026-08-21

ticker close 1d 30d vs XLV 30d

LLYEli Lilly 1,255.95 +0.9% +6.1% -2.2%

VKTXViking Therapeutics 33.71 -1.9% -4.7% -13.0%

WSTWest Pharmaceutical 352.84 -0.3% -0.7% -8.9%

// the daily evidence · every signal scored from −2 to +2

a signal is one thing this bet depends on, scored every weekday. what the world did counts triple over what the price did.

mass_market_uptake what the world did · counts 3× ·

the expansion itself: pill prescriptions, patient counts, Medicare and cash pay enrollment

payer_moves what the world did · counts 3× ·

who pays: insurer and government coverage decisions and price cuts

challenger_data what the world did · counts 3× ·

the next drugs: trial results and deals for the challengers chasing Lilly and Novo

price_momentum what the price did · counts 1× ·

30d relative performance vs XLV

strongly supports · supports · neutral · against · strongly against · one square per weekday

// the tape · this bet, day by day

08-21 no new read today, yesterday's evidence still stands

// the headlines · the last 7 days the machine read for this bet

no headlines collected yet. the first run lands tomorrow at 07:00 CET